Patents by Inventor Andreas Vente

Andreas Vente has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10485805
    Abstract: It was found that finafloxacin eradicates pathogens from patients suffering from bacterial infections like urinary tract infections and pyelonephritis more quickly than other fluoroquinolones regularly used for the treatment of these patients. Due to the efficacy of finafloxacin reduced treatment durations without increasing the daily dosage of finafloxacin and at the same time no or shorter stays in hospital are realizable, thus improving patient convenience and significantly lowering the costs of hospitalization and treatment. Reduced hospitalization periods do also clearly reduce the risk of nosocomial infections and of generating drug-resistant strains through extended therapy. The inventive treatment regimens comprise an oral finafloxacin administration for 1-5 days or a parenteral finafloxacin administration for 1-5 days for use in the treatment of a complicated urinary tract infection or pyelonephritis. However, a prior short parenteral administration of finafloxacin (e.g.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: November 26, 2019
    Assignee: MerLion Pharmaceuticals Pte. Ltd.
    Inventors: Christine Bentley, Carsten Fischer, Mark L├╝ckermann, Andreas Vente, Sven-Eric Wohlert
  • Publication number: 20170354661
    Abstract: It was found that finafloxacin eradicates pathogens from patients suffering from bacterial infections like urinary tract infections and pyelonephritis more quickly than other fluoroquinolones regularly used for the treatment of these patients. Due to the efficacy of finafloxacin reduced treatment durations without increasing the daily dosage of finafloxacin and at the same time no or shorter stays in hospital are realizable, thus improving patient convenience and significantly lowering the costs of hospitalization and treatment. Reduced hospitalization periods do also clearly reduce the risk of nosocomial infections and of generating drug-resistant strains through extended therapy. The inventive treatment regimens comprise an oral finafloxacin administration for 1-5 days or a parenteral finafloxacin administration for 1-5 days for use in the treatment of a complicated urinary tract infection or pyelonephritis. However, a prior short parenteral administration of finafloxacin (e.g.
    Type: Application
    Filed: November 10, 2015
    Publication date: December 14, 2017
    Inventors: Christine Bentley, Carsten Fischer, Mark L├╝ckermann, Andreas Vente, Sven-Eric Wohlert
  • Publication number: 20170326151
    Abstract: It was found that finafloxacin has a high solubility in the presence of Tris. Such solubility is significantly higher than in the presence of other compounds typically used as buffers (e.g. phosphate buffer). The observed significant increase in solubility of finafloxacin in compositions comprising Tris is further advantageously accompanied by a long term stability of such solutions. Tris is therefore to be regarded as a specific tool to considerably enhance the solubility of finafloxacin in solutions. By preparing compositions comprising Tris it is possible to dissolve finafloxacin in such an amount therein that these compositions can effectively be used as parenteral compositions for the treatment of bacterial infections.
    Type: Application
    Filed: October 9, 2015
    Publication date: November 16, 2017
    Applicant: MerLion Pharmaceuticals Pte. Ltd.
    Inventors: Carsten Fischer, Andreas Vente, Sven-Eric Wohlert
  • Patent number: 7795207
    Abstract: The invention relates to a pharmaceutical composition comprising as an active agent a lipopeptide in a physiologically effective dose and a cyclodextrin or a cyclodextrin derivative.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: September 14, 2010
    Inventors: Harald Labischinski, Stefan Pelzer, Horst Priefert, Andreas Vente, Sven-Eric Wohlert
  • Publication number: 20070219124
    Abstract: The invention relates to a pharmaceutical composition comprising as an active agent a lipopeptide in a physiologically effective dose and a cyclodextrin or a cyclodextrin derivative.
    Type: Application
    Filed: November 21, 2006
    Publication date: September 20, 2007
    Applicant: Combinature Biopharm AG
    Inventors: Harald Labischinski, Stefan Pelzer, Horst Priefert, Andreas Vente, Sven-Eric Wohlert
  • Patent number: 6506611
    Abstract: A freely traversable metering head with numerous metering devices, wherein the metering devices are each provided individually or block-by-block with an activating device, and wherein a controller traversable with the metering head is designed for the independent operation of one or more activating devices. Metering devices for such a metering head and procedures for their use are also disclosed.
    Type: Grant
    Filed: February 5, 2001
    Date of Patent: January 14, 2003
    Assignee: Deutsches Resourcenzentrum fur Genomforschung GmbH
    Inventors: Klaus Bienert, Andreas Vente, Heiko Kraack, Rolf Zettl
  • Publication number: 20010019845
    Abstract: A freely traversable metering head with numerous metering devices, wherein the metering devices are each provided individually or block-by-block with an activating device, and wherein a controller traversable with the metering head is designed for the independent operation of one or more activating devices. Metering devices for such a metering head and procedures for their use are also disclosed.
    Type: Application
    Filed: February 5, 2001
    Publication date: September 6, 2001
    Inventors: Klaus Bienert, Andreas Vente, Heiko Kraack, Rolf Zettl